prikaz prve stranice dokumenta Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem
  Preuzmi
PDF 601.53 KB
Znanstveni rad - Izvorni znanstveni rad
Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem
Biomedicines, 10 (2022), 11; 2892. https://doi.org/10.3390/biomedicines10112892
Sertić, Zrinka; Lucijanić, Marko; Bašić-Kinda, Sandra; Serventi Seiwerth, Ranka; Periša, Vlatka; Sertić, Dubravka; Coha, Božena; Pulanić, Dražen; Perić, Zinaida; Desnica, Lana; Mikulić, Mirta; Vodanović, Marijo; Radman-Livaja, Ivo; Šegulja, Dragana; Rogić, Dunja; Valković, Toni; Aurer, Igor; Duraković, Nadira Više autora...

Citirajte ovaj rad

Sertić, Z., Lucijanić, M., Bašić Kinda, S., Serventi Seiwerth, R., Periša, V., Sertić, D. ... Duraković, N. (2022). Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem. Biomedicines, 10. (11). doi: 10.3390/biomedicines10112892

Sertić, Zrinka, et al. "Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem." Biomedicines, vol. 10, br. 11, 2022. https://doi.org/10.3390/biomedicines10112892

Sertić, Zrinka, Marko Lucijanić, Sandra Bašić Kinda, Ranka Serventi Seiwerth, Vlatka Periša, Dubravka Sertić, Božena Coha, et al. "Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem." Biomedicines 10, br. 11 (2022). https://doi.org/10.3390/biomedicines10112892

Sertić, Z., et al. (2022) 'Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem', Biomedicines, 10(11). doi: 10.3390/biomedicines10112892

Sertić Z, Lucijanić M, Bašić Kinda S, Serventi Seiwerth R, Periša V, Sertić D, i sur.. Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem. Biomedicines [Internet]. 11.11.2022. [pristupljeno 18.12.2024.];10(11). doi: 10.3390/biomedicines10112892

Z. Sertić, et al., "Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem", Biomedicines, vol. 10, br. 11, Studeni 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:409104. [Citirano: 18.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:409104
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem
AutorZrinka Sertić
AutorMarko Lucijanić
AutorSandra Bašić-Kinda
AutorRanka Serventi Seiwerth
AutorVlatka Periša
AutorDubravka Sertić
AutorBožena Coha
AutorDražen Pulanić
AutorZinaida Perić
AutorLana Desnica
AutorMirta Mikulić
AutorMarijo Vodanović
AutorIvo Radman-Livaja
AutorDragana Šegulja
AutorDunja Rogić
AutorToni Valković
AutorIgor Aurer
AutorNadira Duraković
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Disease- and treatment-mediated immunodeficiency might render SARS-CoV-2 vaccines less effective in patients with hematologic diseases. We performed a prospective non-interventional study to evaluate humoral response after one and two doses of mRNA-1273, BNT162b2, or ChAdOx1 nCoV-19 vaccine in 118 patients with different malignant or non-malignant hematologic diseases from three Croatian treatment centers. An electrochemiluminescent assay was used to measure total anti-SARS-CoV-2 S-RBD antibody titers. After one vaccine dose, 20/66 (33%) achieved seropositivity with a median antibody titer of 6.1 U/mL. The response rate (58/90, 64.4%) and median antibody titer (>250 U/mL) were higher after two doses. Seropositivity varied with diagnosis (overall p < 0.001), with the lowest rates in lymphoma (34.6%) and chronic lymphocytic leukemia (52.5%). The overall response rate in chronic myeloproliferative neoplasms (CMPN) was 81.3% but reached 100% in chronic myeloid leukemia and other non-myelofibrosis CMPN. At univariable analysis, age > 67 years, non-Hodgkin’s lymphoma, active treatment, and anti-CD20 monoclonal antibody therapy increased the likelihood of no vaccine response, while hematopoietic stem cell recipients were more likely to respond. Age and anti-CD20 monoclonal antibody therapy remained associated with no response in a multivariable model. Patients with the hematologic disease have attenuated responses to SARS-CoV-2 vaccines, and significant variations in different disease subgroups warrant an individualized approach.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaBiomedicines
Brojčani podacivol. 10, br. 11, 2892
e-ISSN2227-9059
DOIhttps://doi.org/10.3390/biomedicines10112892
URN:NBNurn:nbn:hr:184:409104
Datum objave publikacije2022-11-11
URL dokumentahttps://www.mdpi.com/2227-9059/10/11/2892
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2023-01-26 21:21:56